GlassScriptPhysician profile
Anna Elizabeth Case
NPI 1831659416
$1,894.36
in general payments reported to CMS, 2019-2025
22 companies · $607 in 2025
The $607 reported for 2025 was more than what 77% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $91.53 · 2023: $340 · 2024: $856 · 2025: $607.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,803.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,802.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $674.53 | 2023-2025 | Airsupra, Farxiga, Breztri |
| Abbvie INC. | $189.10 | 2023-2025 | Vraylar |
| Novo Nordisk INC | $159.60 | 2023-2025 | Ozempic, Rybelsus |
| Glaxosmithkline, LLC. | $128.54 | 2023 | Jesduvroq, Arexvy, Shingrix |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $113.14 | 2025 | Caplyta |
| Vapotherm INC | $91.53 | 2022 | |
| Lexicon Pharmaceuticals, INC. | $86.26 | 2023-2024 | Inpefa |
| Lilly USA, LLC | $75.31 | 2023-2024 | Mounjaro, Jardiance |
| Phathom Pharmaceuticals, INC. | $74.80 | 2024 | Voquezna |
| Boehringer Ingelheim Pharmaceuticals, INC. | $37.35 | 2024 | |
| Ibsa Pharma INC. | $35.44 | 2024 | Tirosint, Licart |
| Esperion Therapeutics, INC. | $35.08 | 2024-2025 | Nexletol |
| Lundbeck LLC | $35.05 | 2024 | Vyepti |
| Otsuka America Pharmaceutical, INC. | $22.29 | 2024 | Nuedexta |
| Medtronic, INC. | $20.52 | 2025 | Intellis Adaptivestim |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $19.73 | 2024 | |
| Pfizer INC. | $18.97 | 2024 | |
| Ardelyx, INC. | $17.32 | 2025 | Ibsrela |
| Astellas Pharma US INC | $16.71 | 2023 | Veozah |
| Shield Therapeutics INC | $14.44 | 2024 | |
| Amgen INC. | $14.39 | 2023 | Repatha |
| Merck Sharp & Dohme LLC | $14.26 | 2023 | Verquvo, Belsomra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anna Case listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.